Outcomes-based studies have confirmed the importance of Ki-67 as a prognostic marker in luminal breast cancers, similar to the prognostic differences seen in luminal A and luminal B disease as identified by molecular gene-expression panels [58,59,60,61]. Here, MKI67 is linked to breast carcinoma.